Isoquinolinesulfonamide Rho-associated protein kinase (ROCK) inhibitor with vasodilatory, anti-inflammatory, and neuroprotective activity
An isoquinolinesulfonamide kinase inhibitor developed by Asahi Kasei as the first clinically approved ROCK inhibitor, registered in Japan and China for cerebral vasospasm after subarachnoid hemorrhage, with expanding investigational applications in pulmonary hypertension, amyotrophic lateral sclerosis, and cardiovascular disease.
Abstract
Fasudil (HA-1077, AT-877), the isoquinolinesulfonamide derivative of the H-series protein kinase inhibitors first described by Hidaka et al. in 1984, is the only Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitor approved for systemic clinical use and the first protein kinase inhibitor to receive regulatory approval for any indication. Developed by Asahi Kasei Pharma (Tokyo, Japan) and marketed as Eril, fasudil has been approved in Japan since 1995 and in China for the treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage, where it is standard of care in Japanese neurosurgical practice. The compound inhibits ROCK by competitive occupation of the ATP-binding domain, with a Ki of approximately 0.33 micromolar against ROCK activity and modest preferential selectivity for ROCK2 (Ki approximately 47 nanomolar) over ROCK1 (Ki approximately 76 nanomolar) in purified kinase assays. Off-target inhibition of protein kinase A, protein kinase G, protein kinase C, and myosin light chain kinase occurs at approximately 5- to 100-fold higher concentrations. The principal metabolic transformation is rapid hepatic conversion to hydroxyfasudil by aldehyde oxidase (not cytochrome P450), producing an active metabolite with ROCK inhibitory potency similar to or greater than the parent compound and a substantially longer plasma half-life (approximately 5.5 hours versus 0.55 hours for fasudil). This metabolic profile renders fasudil effectively a prodrug of hydroxyfasudil in the oral context. The clinical evidence base in cerebral vasospasm rests on a pivotal 267-patient double-blind placebo-controlled trial (Shibuya et al. 1992) demonstrating significant reductions in angiographic vasospasm (38 versus 61 percent), symptomatic vasospasm (35 versus 50 percent), and poor outcome on the Glasgow Outcome Scale (12 versus 26 percent), confirmed by a 1,462-patient postmarketing surveillance study and a meta-analysis of 8 trials (odds ratio 0.48 for symptomatic vasospasm). Head-to-head comparison with nimodipine demonstrated comparable or superior outcomes (74.5 versus 61.7 percent good clinical outcome). Expanding investigational programs span pulmonary arterial hypertension, where meta-analyses of up to 865 patients demonstrate significant reductions in pulmonary artery pressure, vascular resistance, and 6-minute walk distance with no serious adverse events; and amyotrophic lateral sclerosis, where the 120-patient ROCK-ALS Phase 2 trial confirmed safety, demonstrated significant electrophysiological biomarker preservation (motor unit number index), and confirmed cerebrospinal fluid penetration of the active metabolite at concentrations matching preclinical efficacy. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Selective glycine transporter type 1 (GlyT1) inhibitor for glutamatergic NMDA receptor enhancement
A potent azabicyclo[3.1.0]hexane methanone GlyT1 inhibitor developed by Boehringer Ingelheim to normalize glutamatergic hypofunction in schizophrenia, distinguished by positive Phase II cognitive efficacy signals (standardized effect size 0.34 on MCCB at 10 mg) and subsequent failure to replicate in the 1835-patient Phase III CONNEX programme.
Abstract
Iclepertin (BI 425809) is a potent and selective inhibitor of glycine transporter type 1 (GlyT1) with an IC50 of 5.0 nanomolar in human SK-N-MC cells, developed by Boehringer Ingelheim for the treatment of cognitive impairment associated with schizophrenia (CIAS). The compound is an orally bioavailable azabicyclo[3.1.0]hexane methanone bearing two trifluoromethyl groups and a methylsulfonyl substituent, with three defined stereocenters and a molecular weight of 512.42 g/mol. By blocking the reuptake of glycine from the synaptic cleft into astrocytes and presynaptic terminals, iclepertin increases synaptic glycine concentration at the glycine-B co-agonist site of the N-methyl-D-aspartate (NMDA) receptor, thereby enhancing glutamatergic neurotransmission. This mechanism addresses the NMDA receptor hypofunction hypothesis of schizophrenia, which posits that reduced glutamatergic signaling contributes to the cognitive deficits observed in the disorder.
Pharmacokinetically, iclepertin exhibits a terminal half-life of 34 to 59 hours, supporting once-daily oral dosing with steady-state conditions achieved by day 6. The compound is metabolized predominantly (90 percent or greater) by cytochrome P450 3A4, rendering it sensitive to strong CYP3A4 inhibitors (approximately 6-fold AUC increase with itraconazole) and inducers (approximately 90 percent AUC reduction with rifampicin).
The Phase II clinical programme produced divergent results across indications. However, a parallel 610-patient Phase II trial in mild-to-moderate Alzheimer’s disease dementia (NCT02788513) failed to demonstrate any dose-response relationship on the ADAS-Cog11 primary endpoint. A subsequent Phase II trial combining iclepertin with computerized cognitive training (NCT03859973, n=200) also failed to meet its primary endpoint. The compound received United States Food and Drug Administration Breakthrough Therapy Designation for CIAS in May 2021. Iclepertin was well tolerated across all trials, with adverse event rates numerically similar to or lower than placebo. The compound is not approved in any jurisdiction.
This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
A phenylethylamine NMDA channel blocker distinguished from ketamine by low channel trapping (54% versus 86%), originally developed by AstraZeneca as a neuroprotectant for acute ischaemic stroke (AR-R 15896AR), repositioned for treatment-resistant depression following the discovery of ketamine’s rapid antidepressant properties, and terminated after a 302-patient Phase IIb trial failed to separate from placebo.
Abstract
Lanicemine (AZD6765, formerly AR-R 15896AR) is a low-trapping, non-competitive N-methyl-D-aspartate (NMDA) receptor channel blocker that binds within the ion channel pore of NR2A- and NR2B-containing NMDA receptor complexes with micromolar affinity (Ki 0.5 to 2.1 micromolar; IC50 approximately 10 micromolar at resting membrane potential in rat cortical neurons). The compound is distinguished from the prototypical NMDA channel blocker ketamine by substantially lower channel trapping (54% versus 86%), a property that confers use-dependent, voltage-dependent blockade with preferential activity on tonically active neurons and minimal psychotomimetic liability. Originally synthesized by Astra (later AstraZeneca) as a neuroprotectant designated AR-R 15896AR, the compound advanced through Phase II trials for acute ischaemic stroke in 175 and 103 patients respectively before the stroke program was terminated owing to tolerability limitations at the high doses required for neuroprotective plasma concentrations. Following the demonstration of rapid antidepressant properties of ketamine in treatment-resistant major depressive disorder by Zarate and colleagues, AstraZeneca repositioned the compound for depression under the designation AZD6765 and the International Nonproprietary Name lanicemine.
The depression clinical program comprised four principal studies.
Pharmacokinetics following intravenous administration are described by a two-compartment model with low systemic clearance (8.1 to 9.4 L/h), a terminal half-life of 10 to 16 hours, and predominantly urinary elimination (93.8% of a radiolabeled dose); the compound does not inhibit or induce CYP3A4 in vivo. Preclinical pharmacology demonstrates antidepressant-like activity in the tail suspension test (1 mg/kg, dependent on PI3K/Akt/mTOR/GSK3-beta signaling), reversal of chronic unpredictable mild stress-induced behavioral and neurometabolic deficits, and neuroprotection comparable to MK-801 in the intrastriatal malonate model without the behavioral side effects of high-trapping NMDA antagonists. The compound is positioned within a comparator landscape that includes esketamine (approved), dextromethorphan/bupropion (approved), rapastinel (Phase 3 failed), memantine (failed for depression), and rislenemdaz (pilot only). Lanicemine is not approved for any indication. It is available as a research-grade compound for in vitro and in vivo investigation; investigators should obtain analytical confirmation of identity and purity on every lot.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
A triarylmethane neurotrophin mimetic identified through in silico screening of BDNF loop-domain pharmacophores, distinguished as the first small molecule to co-activate TrkB and TrkC receptors with preclinical efficacy across aging, Alzheimer’s disease, Huntington’s disease, traumatic brain injury, and corneal neuropathy models.
Abstract
LM22B-10 (CAS 342777-54-2) is a non-peptide, blood-brain barrier permeant, triarylmethane small molecule that co-activates tropomyosin-related kinase B (TrkB) and tropomyosin-related kinase C (TrkC) neurotrophin receptors. It was identified by Yang, Massa, and Longo at Stanford University through in silico screening with a brain-derived neurotrophic factor (BDNF) loop-domain pharmacophore, coupled with low-throughput neuronal survival screening, and was first reported in Neuropharmacology in 2016. LM22B-10 is distinguished from prior small-molecule Trk ligands, which typically activate a single receptor subtype, by its dual activation of TrkB (EC50 approximately 1.8 micromolar) and TrkC (EC50 approximately 2.5 micromolar), producing neurotrophic activity with an EC50 for neuronal survival of 200 to 300 nanomolar that exceeds the effects of recombinant BDNF and neurotrophin-3 (NT-3), individually and in combination, in hippocampal neuronal assays. The compound selectively activates TrkB and TrkC without engaging TrkA, and drives downstream Akt and ERK1/2 signaling in vitro and in vivo. Preclinical studies in aged mice demonstrated that LM22B-10 activates hippocampal and striatal TrkB and TrkC signaling, increases dendritic spine density, and supports neuronal integrity. In mouse models of Huntington’s disease (R6/2 and Q140), the compound reduced intranuclear huntingtin aggregates, dendritic spine loss, microglial activation, and degeneration of medium spiny neurons while improving motor performance. In a rat controlled cortical impact model of traumatic brain injury, LM22B-10 at 10 mg/kg intraperitoneal reduced cortical cell death by approximately 59 percent and increased hippocampal doublecortin-positive neurogenesis by approximately 65 percent, with concurrent improvement in spatial memory and anxiety-related behavior in injured animals. The compound has also demonstrated corneal nerve regeneration in both healthy and diabetic mouse wound models when delivered as topical eye drops. A derivative, PTX-BD10-2, was developed by PharmatrophiX with improved oral bioavailability and has demonstrated prevention of cholinergic neuron atrophy, restoration of hippocampal long-term potentiation, and normalization of synaptic function in late-stage Alzheimer’s disease mouse models (hAPPLond/Swe) following chronic oral dosing. The mechanism of TrkB/TrkC activation by LM22B-10 is not without controversy. An independent validation study using microscale thermophoresis reported weak binding to the TrkB extracellular domain (Kd approximately 83 micromolar) and failure to induce TrkB, Akt, or ERK1/2 phosphorylation in conventional blotting assays, results that contrast with the original characterization. A 2025 review in the Journal of Medicinal Chemistry proposed that LM22B-10 and related putative Trk agonists may function as positive allosteric modulators binding the transmembrane domain rather than as classical orthosteric agonists. The discrepancy remains unresolved and constitutes a significant open question in the field. LM22B-10 has not entered clinical trials; it remains a preclinical research tool. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Dual peroxisome proliferator-activated receptor delta/gamma (PPARd/g) agonist with primary PPARd selectivity and brain-penetrant insulin-sensitizing activity
A non-thiazolidinedione dual nuclear receptor agonist originally developed for metabolic disease and repositioned as a first-in-class brain insulin-sensitizing therapy for Alzheimer’s disease, distinguished by concurrent PPARd and PPARg activation, high central nervous system penetrance, and Phase 2 evidence of disease-modifying effects on cognition and amyloid biomarkers.
Abstract
T3D-959 (DB-959, DB-959Na as the sodium salt) is an orally bioavailable, brain-penetrant, non-thiazolidinedione dual agonist of peroxisome proliferator-activated receptor delta (PPARd; human ED50 19 nM) and peroxisome proliferator-activated receptor gamma (PPARg; human ED50 297 nM), conferring approximately 15-fold selectivity for the delta isoform. The compound was originally synthesized by Bayer and advanced through Phase 1 clinical trials for dyslipidemia and type 2 diabetes by DARA BioSciences before being acquired in 2013 by T3D Therapeutics and repositioned as a disease-modifying candidate for Alzheimer’s disease (AD) on the basis of the “type 3 diabetes” hypothesis, which posits that sporadic AD is driven by progressive brain insulin resistance, deficient insulin and insulin-like growth factor signaling, and consequent neurometabolic dysfunction. T3D-959 is the first PPARd-activating compound to enter clinical development for AD and represents a mechanistically distinct approach from the anti-amyloid antibody and cholinesterase inhibitor classes that dominate the current AD therapeutic landscape. Preclinical characterization in the intracerebral streptozotocin (i.c. Therapeutic effects were observed even when treatment was delayed seven days after the STZ insult, suggesting relevance to mild and moderate disease stages. A separate preclinical study demonstrated that T3D-959 at 1.0 mg/kg/day improved motor function and prevented cerebellar white matter atrophy in the same model. Pharmacokinetic analysis confirmed dose-dependent systemic exposure exceeding the PPARd ED50 at all doses tested. Plasma metabolomics showed dose-dependent reductions in branched-chain amino acids and ceramides and increases in acylcarnitines, consistent with improved insulin sensitivity and enhanced fatty acid beta-oxidation. FDG-PET neuroimaging demonstrated dose-dependent increases in regional cerebral glucose metabolism, with the strongest effects in the putamen, anterior cingulate, insula, and orbital frontal cortex. The Phase 2 PIONEER trial, a 24-week multicenter randomized double-blind placebo-controlled study in 250 patients with mild to moderate AD, reported positive top-line results in November 2023 at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) conference. In the modified intent-to-treat population (n=141), the 30 mg group showed improvement on ADAS-Cog11 (0.73 versus 2.70 on placebo; p=0.073), and the 15 mg group showed improvement on ADCS-CGIC (0.39 versus 0.86 on placebo; p=0.060). Plasma amyloid beta 42/40 ratio improved significantly in the 30 mg (p=0.011) and 45 mg (p=0.033) groups, and the neurodegeneration marker neurogranin improved significantly in the 30 mg group (p=0.035). The compound was well tolerated, with adverse event rates similar between active and placebo arms (37.3% versus 43.1%) and no treatment-related serious adverse events. T3D-959 is not approved for any indication in any jurisdiction. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
N-acetylgalactosamine-conjugated small interfering RNA (GalNAc-siRNA) targeting hepatic LPA messenger RNA for lipoprotein(a) reduction
A synthetic, chemically modified, GalNAc-conjugated siRNA developed by Arrowhead Pharmaceuticals and licensed to Amgen that silences hepatic LPA gene expression through RNA interference, producing sustained and near-complete reduction of circulating lipoprotein(a) concentrations in patients with established atherosclerotic cardiovascular disease.
Abstract
Olpasiran (AMG 890; formerly ARO-LPA) is an investigational, first-in-class, synthetic double-stranded small interfering RNA (siRNA) conjugated to a trivalent N-acetylgalactosamine (GalNAc) ligand for selective hepatocyte delivery via the asialoglycoprotein receptor (ASGPR). The compound targets the messenger RNA transcribed from the LPA gene, which encodes apolipoprotein(a), the defining protein component of lipoprotein(a) [Lp(a)]. Elevated Lp(a) is a genetically determined, independent, and causal risk factor for atherosclerotic cardiovascular disease (ASCVD), aortic valve stenosis, and thrombotic events, affecting an estimated 20 to 30 percent of the global population at concentrations associated with increased cardiovascular risk. Prior to the development of RNA-targeted therapies, no pharmacologic intervention produced clinically meaningful reduction in Lp(a) concentration; niacin and PCSK9 inhibitors achieve modest decreases of 20 to 30 percent, insufficient to test the causal hypothesis relating Lp(a) lowering to cardiovascular event reduction.
Following uptake into hepatocytes through ASGPR-mediated endocytosis, the antisense strand of olpasiran incorporates into the RNA-induced silencing complex (RISC), which catalytically cleaves LPA mRNA and suppresses de novo synthesis of apolipoprotein(a). The resulting reduction in hepatic apolipoprotein(a) secretion produces a dose-dependent, sustained, and near-complete lowering of circulating Lp(a) particles. In the Phase 1 single ascending-dose trial (NCT03626662), olpasiran produced dose-dependent Lp(a) reductions of 71 to 97 percent that persisted for several months after a single subcutaneous injection, with effects lasting up to six months at higher doses [1].
The serum pharmacokinetics of olpasiran are characterized by rapid absorption after subcutaneous injection (time to maximum concentration approximately 3 to 9 hours) and rapid clearance from the systemic circulation (serum half-life approximately 3 to 8 hours), consistent with efficient hepatocyte uptake via the GalNAc-ASGPR pathway. The pharmacodynamic effect is dissociated from serum drug concentrations: the prolonged Lp(a) lowering reflects the intracellular persistence of the active RISC complex in hepatocytes rather than circulating drug exposure. The compound is well tolerated. In the OCEAN(a)-DOSE trial, the overall incidence of adverse events was similar in the olpasiran and placebo arms; the most frequently reported treatment-related adverse event was mild injection-site pain, which resolved without intervention [2]. No clinically significant changes in hepatic, renal, hematologic, or glycemic laboratory parameters were observed.
Olpasiran is currently under evaluation in the Phase 3 OCEAN(a)-Outcomes trial (NCT05581303), a large cardiovascular outcomes study assessing the effect of olpasiran versus placebo on the composite endpoint of coronary heart disease death, myocardial infarction, or urgent coronary revascularization in participants with ASCVD and elevated Lp(a). An additional Phase 3 primary prevention trial, OCEAN(a)-PreEvent (NCT07136012), is evaluating olpasiran for prevention of first major cardiovascular events. The compound is not approved by any regulatory authority as of the date of this monograph. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
A potent, orally active aminopyrimidine developed at Chiron Corporation as a selective dual-isoform GSK-3 inhibitor, distinguished by sub-10-nanomolar potency against both GSK-3alpha and GSK-3beta with greater than 500-fold selectivity over closely related kinases, and now the most widely deployed small-molecule Wnt pathway activator in stem cell biology, directed differentiation, chemical reprogramming, and regenerative medicine research.
Abstract
CHIR-99021 (CT99021, laduviglusib) is a synthetic aminopyrimidine derivative and the most potent and selective small-molecule inhibitor of glycogen synthase kinase 3 (GSK-3) in current research and clinical use, with half-maximal inhibitory concentrations of approximately 10 nM against GSK-3alpha and 6.7 nM against GSK-3beta. The compound was developed at Chiron Corporation in the early 2000s as part of a medicinal chemistry program targeting GSK-3 for the treatment of type 2 diabetes mellitus, and was first characterized in the seminal Ring et al. (2003) publication demonstrating that selective GSK-3 inhibition potentiates insulin-stimulated glucose transport and utilization both in vitro and in vivo [1]. CHIR-99021 achieves its selectivity through an aminopyrimidine scaffold bearing a 2,4-dichlorophenyl substituent and a 5-methyl-1H-imidazol-2-yl group, producing greater than 500-fold selectivity for GSK-3 over 20 closely related protein kinases and greater than 800-fold selectivity across a broader panel of 23 additional enzymes and 22 receptors [1, 2].
The principal pharmacological consequence of GSK-3 inhibition by CHIR-99021 is stabilization of cytoplasmic beta-catenin through prevention of its phosphorylation-dependent proteasomal degradation. Accumulated beta-catenin translocates to the nucleus and transactivates Wnt-responsive genes through interaction with T-cell factor/lymphoid enhancer factor (TCF/LEF) family transcription factors, producing a pharmacological activation of the canonical Wnt/beta-catenin signaling pathway that is functionally equivalent to Wnt ligand stimulation. This mechanism has made CHIR-99021 the standard small-molecule Wnt pathway activator in stem cell biology and regenerative medicine, where it is deployed in the “2i” naive pluripotency medium (in combination with the MEK inhibitor PD0325901) for maintenance of mouse embryonic stem cells, in directed differentiation protocols for the generation of cardiomyocytes, neural progenitor cells, pancreatic beta cells, and hematopoietic progenitors from human pluripotent stem cells, and in chemical reprogramming cocktails for the generation of induced pluripotent stem cells from somatic cells without genetic manipulation [3, 4, 5].
The compound has also been identified as a component of chemical cocktails for direct reprogramming of fibroblasts to cardiomyocytes and to chemically induced pluripotent stem cells (CiPSCs) [9, 10].
Pharmacokinetic characterization in rodents demonstrates oral bioavailability sufficient for in vivo efficacy studies, though the compound is used predominantly as an in vitro research tool and has not been independently advanced through human pharmacokinetic characterization outside the FX-322 combination formulation. Safety considerations include the potential for off-target effects on dopaminergic neurotransmission, with ex vivo studies demonstrating that CHIR-99021 causes inactivation of tyrosine hydroxylase and depletion of dopamine in rat brain striatum, a finding that warrants consideration in the design of in vivo studies and in the interpretation of central nervous system effects [11]. The compound is supplied as a research-grade preparation by multiple chemical suppliers at greater than 98 percent purity; investigators should confirm identity and purity on every lot and should prepare stock solutions in dimethyl sulfoxide owing to the limited aqueous solubility of the free base form.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
GalNAc3-conjugated 2′-MOE antisense oligonucleotide targeting apolipoprotein(a) mRNA for lipoprotein(a) reduction
A hepatocyte-directed, triantennary N-acetylgalactosamine-conjugated antisense oligonucleotide developed by Ionis Pharmaceuticals and licensed to Novartis, designed to selectively reduce circulating lipoprotein(a) concentrations by RNase H1-mediated degradation of apolipoprotein(a) mRNA in hepatocytes, currently under evaluation in the Phase 3 Lp(a)HORIZON cardiovascular outcomes trial.
Abstract
Pelacarsen (ISIS 681257; also designated IONIS-APO(a)-LRx, AKCEA-APO(a)-LRx, and TQJ230) is a second-generation, hepatocyte-directed antisense oligonucleotide (ASO) conjugated to a triantennary N-acetylgalactosamine (GalNAc3) ligand, designed to reduce circulating lipoprotein(a) [Lp(a)] concentrations by selective inhibition of apolipoprotein(a) [apo(a)] synthesis in the liver. The compound targets the messenger RNA transcribed from the LPA gene, binding with high specificity and triggering RNase H1-mediated cleavage and subsequent degradation of the transcript, thereby preventing translation of the apo(a) protein that is the defining structural component of the Lp(a) particle.
Lipoprotein(a) is a genetically determined, independent, and causal risk factor for atherosclerotic cardiovascular disease (ASCVD), calcific aortic valve stenosis (CAVS), and thrombotic events. Plasma Lp(a) concentrations are primarily determined by LPA gene variation and are minimally responsive to lifestyle modification or conventional lipid-lowering pharmacotherapy including statins, ezetimibe, and PCSK9 inhibitors. Approximately 20 to 25 percent of the global population carries Lp(a) concentrations above 50 mg/dL, the threshold at which epidemiological and Mendelian randomization data consistently demonstrate elevated cardiovascular risk. Prior to the development of targeted Lp(a)-lowering agents, no pharmacotherapy had demonstrated selective, potent, and sustained reduction of Lp(a) in a manner suitable for chronic cardiovascular risk management.
The compound was well tolerated; the principal adverse events were mild injection site reactions.
Enrollment was completed in 2022; topline results are anticipated in 2026. A companion Phase 3 trial (Lp(a)FRONTIERS CAVS) evaluates pelacarsen in calcific aortic valve stenosis progression. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Selective small-molecule allosteric inhibitor of cardiac beta-myosin heavy chain (MYH7) ATPase activity
A next-generation cardiac myosin inhibitor developed by Cytokinetics as CK-3773274, engineered for optimized pharmacokinetic properties relative to mavacamten, approved by the United States Food and Drug Administration in December 2025 for the treatment of symptomatic obstructive hypertrophic cardiomyopathy under the trade name MYQORZO.
Abstract
Aficamten (CK-3773274, trade name MYQORZO) is a selective, allosteric, reversible small-molecule inhibitor of cardiac myosin motor activity developed by Cytokinetics, Inc. for the treatment of hypertrophic cardiomyopathy (HCM). The compound reduces myocardial contractility by stabilizing a weak actin-binding, pre-power-stroke state of the beta-cardiac myosin head, thereby decreasing the number of functional myosin cross-bridges available during each cardiac cycle and attenuating the left ventricular outflow tract (LVOT) obstruction that drives symptoms in obstructive HCM. Aficamten binds to an allosteric site between the upper 50 kDa and lower 50 kDa subdomains of the myosin catalytic domain, overlapping with the blebbistatin binding pocket but distinct from the mavacamten binding site, and dramatically slows phosphate release from the myosin ATPase cycle to a rate slower than the conventional super-relaxed state.
The compound was engineered to address pharmacokinetic limitations of mavacamten, the first-in-class cardiac myosin inhibitor. Aficamten achieves a plasma elimination half-life of approximately 75 to 100 hours (compared to 7 to 9 days for mavacamten), reaches steady-state plasma concentrations within approximately 2 weeks of daily dosing (compared to approximately 6 weeks for mavacamten), demonstrates reversibility of pharmacodynamic effects within 24 to 48 hours, exhibits a shallow exposure-response relationship that widens the therapeutic window, and is metabolized by multiple cytochrome P450 enzymes (CYP2C9, CYP3A4, CYP2D6, CYP2C19) rather than predominantly by the polymorphic CYP2C19, thereby reducing the drug-drug interaction burden and eliminating the requirement for CYP metabolizer genotyping.
Clinical development of aficamten has proceeded through a comprehensive program. The Phase 1 dose-escalation study in 102 healthy participants demonstrated dose-proportional pharmacokinetics, dose-dependent reductions in left ventricular ejection fraction (LVEF), and favorable tolerability with no serious adverse events. The Phase 2 REDWOOD-HCM trial in patients with symptomatic obstructive HCM demonstrated statistically significant reductions in resting and post-Valsalva LVOT gradients, with 78.6 to 92.9 percent of patients achieving target gradient reduction at 10 weeks. The pivotal Phase 3 SEQUOIA-HCM trial randomized 282 patients with symptomatic obstructive HCM to aficamten or placebo for 24 weeks and met its primary endpoint of improved peak oxygen uptake (pVO2), with a least-squares mean difference of 1.74 mL/kg/min (p = 0.000002), along with statistically significant improvements in all 10 prespecified secondary endpoints including NYHA functional class, Kansas City Cardiomyopathy Questionnaire scores, and LVOT gradient reduction. The Phase 3 MAPLE-HCM trial demonstrated superiority of aficamten monotherapy over metoprolol monotherapy, with a pVO2 least-squares mean difference of 2.3 mL/kg/min (p < 0.0001). The Phase 3 ACACIA-HCM trial in 516 patients with non-obstructive HCM met both dual primary endpoints for symptom burden and exercise capacity improvement.
The United States Food and Drug Administration approved aficamten on December 19, 2025, for the treatment of adults with symptomatic obstructive HCM to improve functional capacity and symptoms, marketed as MYQORZO. The approval includes a boxed warning regarding the risk of heart failure due to systolic dysfunction and a Risk Evaluation and Mitigation Strategy (REMS) requiring echocardiographic monitoring. The principal adverse reaction observed at greater than 5 percent incidence above placebo was hypertension (8 percent versus 2 percent). LVEF reduction below 50 percent occurred in 3.5 percent of aficamten-treated patients in SEQUOIA-HCM compared to 0.7 percent on placebo; all instances were mild, reversible, and not associated with clinical heart failure events. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Long-acting Fc-fusion fibroblast growth factor 21 (FGF21) analog with direct antifibrotic, anti-steatotic, and metabolic regulatory activity
An engineered, once-monthly IgG1-Fc-fused FGF21 analog developed by Novartis and advanced through Boston Pharmaceuticals and GSK for the treatment of metabolic dysfunction-associated steatohepatitis, distinguished from other FGF21 analogs by a 21-day pharmacokinetic half-life that permits monthly subcutaneous dosing and by Phase 2 evidence of fibrosis reversal and MASH resolution in patients with moderate-to-advanced hepatic fibrosis.
Abstract
Efimosfermin alfa (formerly LLF580 under Novartis origination, subsequently designated BOS-580 under Boston Pharmaceuticals development, and now GSK-6519754 following acquisition by GSK plc) is a genetically engineered, long-acting analog of human fibroblast growth factor 21 (FGF21), a hepatokine and adipokine that regulates hepatic lipid oxidation, adipose tissue glucose uptake, triglyceride metabolism, and inflammatory signaling through formation of a ternary complex with the transmembrane tyrosine kinase FGF receptor 1c (FGFR1c) and the obligate co-receptor beta-klotho (KLB). The molecule is a homodimeric fusion protein in which two copies of a stabilized FGF21 variant are fused at their N-termini to the crystallizable fragment (Fc) of human immunoglobulin G1 (IgG1). The FGF21 domain is further stabilized by the introduction of a non-native disulfide bond and point mutations that increase proteolytic resistance, together producing a pharmacokinetic half-life of approximately 21 days in humans and enabling subcutaneous administration once every four weeks. This dosing interval distinguishes efimosfermin from the weekly-dosed FGF21 analogs efruxifermin (Akero Therapeutics) and pegozafermin (89bio), which require subcutaneous injection every one to two weeks.
In May 2025, GSK plc completed acquisition of efimosfermin from Boston Pharmaceuticals for 1.2 billion United States dollars upfront and up to 800 million dollars in milestone payments, with tiered royalties owed to Novartis Pharma AG. The compound has received United States Food and Drug Administration Breakthrough Therapy Designation and European Medicines Agency Priority Medicines (PRIME) Designation for the treatment of MASH. Phase 3 development (the ZENITH program) commenced in December 2025, with a potential first launch projected for 2029. GSK has indicated development plans in both MASH (including compensated cirrhosis) and alcohol-related liver disease (ALD), with potential for combination therapy with GSK’990, a complementary hepatology pipeline candidate. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.